Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Sees No Impact From Imports; Not Attractive To “Parallel Traders”

Executive Summary

Schering-Plough sees one advantage to operating as a smaller pharmaceutical player: little or no impact from a potential U.S.-sanctioned drug importation policy

You may also be interested in...

Senate GOP Import Bill Will Start With Canada, Leave Expansion Up To FDA

The Senate Republican leadership's reimportation bill will focus on wholesale imports from Canada and leave any decision about future expansions in parallel trade up to FDA

AARP Supports Canadian Imports To Place “Downward Pressure” On Rx Costs

AARP is endorsing prescription drug reimportation from Canada as a measure to help control the cost of drugs

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts